When Ozempic and Wegovy hit the FDA shortage list in 2022, compounding pharmacies stepped in with cheaper semaglutide. Millions of Americans got treatment they could afford. In late 2024 and 2025, the shortage officially ended, and the rules changed. Here is what you need to know in 2026.
What "Compounded" Actually Means
Compounding is when a pharmacy mixes a customized medication for a specific patient. It is legal and useful when someone needs a form the manufacturer does not make, a dye-free version, an unusual dose, or a drug on the FDA shortage list.
During the shortage, 503A compounding pharmacies were allowed to make semaglutide because patients could not get the branded product. That exception no longer applies.
What Changed in 2024–2026
- October 2024: FDA declared tirzepatide (Mounjaro/Zepbound) no longer in shortage. Compounded tirzepatide became largely non-compliant.
- February 2025: Same for semaglutide (Ozempic/Wegovy).
- Late 2025: FDA enforcement actions and lawsuits accelerated. Most legitimate 503A pharmacies stopped compounding these drugs.
- 2026: Novo Nordisk launched a direct cash-pay option for Wegovy (
$499/mo). Lilly followed with LillyDirect for Zepbound ($349–$499/mo depending on dose).
Are Compounded Versions Safe?
Mixed answer:
In favor: Millions of doses have been administered with generally acceptable safety records when sourced from reputable 503B facilities.
Against:
- Salt forms (semaglutide sodium, semaglutide acetate) are chemically different from the FDA-approved base and have almost no clinical trial data.
- Dosing errors are more common, vials with unclear concentrations, patient-drawn syringes.
- Additives vary between pharmacies (B12, glycine, etc.) and are not always disclosed.
- Sterility depends entirely on the pharmacy, the FDA has issued warning letters to multiple facilities.
If you are on a compounded GLP-1, ask two questions: (1) Is this the semaglutide base or a salt form? (2) Is my pharmacy a 503B outsourcing facility registered with the FDA? If either answer is unclear, work with your prescriber on a transition plan.
Cost Comparison (Mid-2026)
| Option | Monthly cost | Notes |
|---|---|---|
| Ozempic (insurance) | $25–$100 copay | Type 2 diabetes only |
| Wegovy (insurance) | $25–$150 copay | Obesity/overweight with comorbidity |
| Wegovy DTC (cash) | ~$499 | Novo NovoCare Pharmacy |
| Zepbound (insurance) | $25–$150 copay | Similar criteria |
| Zepbound vials (cash) | $349–$499 | LillyDirect, self-administered |
| Compounded (2023) | $150–$300 | Increasingly unavailable |
The branded cash-pay routes have narrowed the compounded price advantage to a few hundred dollars, with none of the sourcing uncertainty.
How to Transition Off a Compound Safely
- Do not just stop. Rebound weight gain and glucose swings are real.
- See your prescriber for a branded prescription (Ozempic if type 2 diabetes, Wegovy or Zepbound if for obesity).
- Check formulary and PA requirements, most insurers require documented BMI, comorbidities, and sometimes prior therapy.
- Consider LillyDirect or NovoCare if insurance denies.
- Match the dose, a 1.7 mg compounded dose does not always translate cleanly to a 1.0 mg branded dose. Your doctor will titrate.
Frequently asked questions
My telehealth clinic still sells compounded semaglutide, is that legal?
Some clinics claim exceptions based on "personalized dosing" or added ingredients. FDA has stated most of these do not qualify. Enforcement is patchy but risks are real, both for the pharmacy and for you.
Are the results the same?
For most users on the semaglutide base form at equivalent doses, yes. For salt forms, data is limited. Anecdotally, some users report less appetite suppression on compounds.
What if I cannot afford the branded version?
Options: (1) Manufacturer patient assistance programs, (2) LillyDirect/NovoCare cash-pay, (3) 340B pricing at community health centers, (4) Consider phentermine or metformin as bridge therapies with your doctor.
Can I stockpile compounds before they disappear?
Do not. Storage matters, expiration matters, and having 6 months of a product with unclear composition is not a plan.
Is compounded tirzepatide safer than compounded semaglutide?
No structural safety difference. Same salt-form and sourcing concerns apply.
The Bottom Line
Compounded GLP-1s were a stopgap during a genuine drug shortage. That era is ending. If you have been paying $200/month for a compound, the branded cash-pay route is now within reach, with real supply chain, real trial data, and real recall protection. Talk to your prescriber this month, not next.